News
2.11.23

TOPADUR, Yonsei University and Juvic Inc. grant awarded

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

Download DocumentDokument herunterladen
5.10.21
Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

Read more
10.9.20
Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

Read more
15.10.21
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more